PET/computed tomography and patient outcomes in melanoma

Eric M. Rohren

doi:10.1016/j.cpet.2014.12.006

PET/computed tomography and patient outcomes in melanoma

Eric M. Rohren

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

The performance of fludeoxyglucose F 18 (FDG)-PET/computed tomography (CT) in the initial and follow-up evaluation of patients with melanoma is well established. Groups are beginning to investigate whether the inclusion of FDG-PET/CT into a staging or surveillance algorithm results in an improvement in patient outcome and whether such an imaging program would be cost-effective.

Original language	English (US)
Pages (from-to)	243-254
Number of pages	12
Journal	PET Clinics
Volume	10
Issue number	2
DOIs	https://doi.org/10.1016/j.cpet.2014.12.006
State	Published - Apr 1 2015

Keywords

Melanoma
Outcomes
PET/CT
Surveillance

ASJC Scopus subject areas

Radiation
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.cpet.2014.12.006

Cite this

@article{02ce2b6038bf456b9e48a4a650663d9c,

title = "PET/computed tomography and patient outcomes in melanoma",

abstract = "The performance of fludeoxyglucose F 18 (FDG)-PET/computed tomography (CT) in the initial and follow-up evaluation of patients with melanoma is well established. Groups are beginning to investigate whether the inclusion of FDG-PET/CT into a staging or surveillance algorithm results in an improvement in patient outcome and whether such an imaging program would be cost-effective.",

keywords = "Melanoma, Outcomes, PET/CT, Surveillance",

author = "Rohren, {Eric M.}",

year = "2015",

month = apr,

day = "1",

doi = "10.1016/j.cpet.2014.12.006",

language = "English (US)",

volume = "10",

pages = "243--254",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - PET/computed tomography and patient outcomes in melanoma

AU - Rohren, Eric M.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - The performance of fludeoxyglucose F 18 (FDG)-PET/computed tomography (CT) in the initial and follow-up evaluation of patients with melanoma is well established. Groups are beginning to investigate whether the inclusion of FDG-PET/CT into a staging or surveillance algorithm results in an improvement in patient outcome and whether such an imaging program would be cost-effective.

AB - The performance of fludeoxyglucose F 18 (FDG)-PET/computed tomography (CT) in the initial and follow-up evaluation of patients with melanoma is well established. Groups are beginning to investigate whether the inclusion of FDG-PET/CT into a staging or surveillance algorithm results in an improvement in patient outcome and whether such an imaging program would be cost-effective.

KW - Melanoma

KW - Outcomes

KW - PET/CT

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=84926143731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926143731&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2014.12.006

DO - 10.1016/j.cpet.2014.12.006

M3 - Review article

C2 - 25829089

AN - SCOPUS:84926143731

SN - 1556-8598

VL - 10

SP - 243

EP - 254

JO - PET Clinics

JF - PET Clinics

IS - 2

ER -

PET/computed tomography and patient outcomes in melanoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this